Last reviewed · How we verify

Propofol/Lidocaine

NYU Langone Health · FDA-approved active Small molecule

Propofol and lidocaine together provide rapid induction and maintenance of anesthesia with reduced pain on injection through synergistic central nervous system depression.

Propofol and lidocaine together provide rapid induction and maintenance of anesthesia with reduced pain on injection through synergistic central nervous system depression. Used for Induction and maintenance of general anesthesia, Sedation in intensive care units.

At a glance

Generic namePropofol/Lidocaine
Also known asPropofol, Fospropofol, Pain on Injection
SponsorNYU Langone Health
Drug classIntravenous anesthetic combination
TargetGABA-A receptor (propofol); voltage-gated sodium channels (lidocaine)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhaseFDA-approved

Mechanism of action

Propofol is an intravenous anesthetic that enhances GABA-mediated inhibition in the central nervous system, producing sedation and unconsciousness. Lidocaine, a local anesthetic, blocks sodium channels and is added to the formulation to reduce the pain and burning sensation that occurs during propofol injection. The combination leverages propofol's anesthetic efficacy while mitigating a common adverse effect.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: